NEWS
Presidential Candidates’ Dueling Child Credit Expansions Explained
The Trump-Vance and Harris-Walz presidential campaigns have each recently proposed large expansions to the child tax credit (CTC). Both proposals might be intended to appeal to similar voters, but they vary significantly regarding budgetary cost, distribution of benefits, and effect on work incentives.
A Tip Exemption Is Not Sound Tax Policy
Earlier this week, Vice President Kamala Harris, campaigning in Nevada, endorsed exempting tips from the individual income tax. This follows former President Donald Trump’s proposal last month to do the same.
Implications of Cannabis Legalization for the US Federal Budget
While the details of future federal legislation and executive actions to legalize, regulate, and tax cannabis remain unknown, such policies could have significant impacts on the federal budget.
Alex Brill Writes to FTC Regarding Interim Pharmacy Benefit Manager Report
In July, MGA CEO Alex Brill submitted a comment letter to the Federal Trade Commission (FTC) expressing concerns about their newly released interim report.
A Balanced Plan for Fiscal Stability and Economic Growth
Our plan seeks to achieve long-term fiscal stability and promote economic growth by aligning federal spending and revenue and pursuing market-based policy reforms.
Despite Headwinds, Biosimilars Market Is Growing in 2024
The Food and Drug Administration (FDA) has approved a record number of biosimilars in 2024, and the year is only half over.
IRS says it will deny most claims of pandemic tax credit for employers
“A big responsibility is falling on the IRS to deal with this problem, when, in fact, Congress could be dealing with this problem,” Brill said.”
Trump Talks Taxes and Tariffs
Former President Trump trotted through Washington last week leaving a trail of policy proposals behind him. Two revenue proposals are worth noting.
Beware the Baseline Manipulator
Over at the Daily Caller, JD Foster recently took aim at an article I wrote about the impending expiration of major provisions of the Tax Cuts and Jobs Act of 2017 (TCJA) on December 31, 2025.
Patent Thicket Déjà Vu
Tuesday’s Senate Judiciary Committee hearing on drug competition was largely as expected: Committee members voiced support for legislative reforms to address features of the current patent system that result in abuses that excessively limit competition.
Will Congress Finally Act on Patent Thickets?
In 2019, the Committee moved legislation to prevent brand drug companies from amassing superfluous patents around their products—a strategy that, as we’ve written before, is uniquely problematic in the United States.
Federal Debt: The Baseline and Options for Reform
On May 13, experts convened at AEI to discuss the United States’ fiscal trajectory: how we got here, where we’re going, and what we can do to reduce the burden of debt for future generations.
Navigating the Upcoming Tax Cliff: Can Republicans Prevent a Tax Increase Without Adding to the Deficit?
On December 22, 2017, President Donald Trump signed into law the Tax Cuts and Jobs Act (TCJA).
Current and Future State of US Biosimilars
Fourteen years ago, Congress established a regulatory pathway for biosimilars, direct competitors to branded biologic drugs.
Trends in the US Insulin Market: New Prices, New Players, New Dynamics
Insulin, a drug first developed more than 100 years ago, has experienced a surge in political interest in recent years following dramatic price hikes.
- Presidential Candidates’ Dueling Child Credit Expansions Explained
- A Tip Exemption Is Not Sound Tax Policy
- Implications of Cannabis Legalization for the US Federal Budget
- Alex Brill Writes to FTC Regarding Interim Pharmacy Benefit Manager Report
- A Balanced Plan for Fiscal Stability and Economic Growth
- Despite Headwinds, Biosimilars Market Is Growing in 2024
- IRS says it will deny most claims of pandemic tax credit for employers
- Trump Talks Taxes and Tariffs
- Beware the Baseline Manipulator
- Patent Thicket Déjà Vu
